Fiebiger, W C <br/><br/>
Absence of therapeutic efficacy of the somatostatin analogue lanreotide in advanced primary hepatic cholangiocellular cancer and adenocarcinoma of the gallbladder despite in vivo somatostatin-receptor expression.  [electronic resource] 

 -  Scandinavian journal of gastroenterology  Feb 2002 
 - 222-5 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>0036-5521 
<br/><br/><label>Standard No.: </label>10.1080/003655202753416911  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Bile Duct Neoplasms--diagnostic imaging<br/>Bile Ducts, Intrahepatic--diagnostic imaging<br/>Cholangiocarcinoma--diagnostic imaging<br/>Female<br/>Gallbladder Neoplasms--diagnostic imaging<br/>Heterocyclic Compounds<br/>Humans<br/>Male<br/>Peptides, Cyclic--therapeutic use<br/>Prospective Studies<br/>Radionuclide Imaging<br/>Radiopharmaceuticals<br/>Receptors, Somatostatin--metabolism<br/>Somatostatin--analogs & derivatives